Moreover, the 36-month beta value for WINT is 0.69. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for WINT is 0.75M and currently, short sellers hold a 124.02% of that float. On July 01, 2025, WINT’s average trading volume was 2.46M shares.
WINT) stock’s latest price update
Windtree Therapeutics Inc (NASDAQ: WINT) has seen a rise in its stock price by 14.82 in relation to its previous close of 0.45. However, the company has experienced a 29.02% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-26 that Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of 2026 Tech transfer underway with validation batch manufacturing expected to begin in 2026 Evofem and Windtree exploring other partnerships WARRINGTON, Pa., June 26, 2025 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (Nasdaq: WINT) today announced that it has contracted with a pharmaceutical manufacturer in China to produce Evofem’s hormone-free contraceptive product, PHEXXI ® (lactic acid, citric acid and potassium bitartrate), at a cost that is significantly below current levels.
WINT’s Market Performance
Windtree Therapeutics Inc (WINT) has experienced a 29.02% rise in stock performance for the past week, with a -34.67% drop in the past month, and a -66.92% drop in the past quarter. The volatility ratio for the week is 16.86%, and the volatility levels for the past 30 days are at 15.55% for WINT. The simple moving average for the past 20 days is -10.38% for WINT’s stock, with a -97.75% simple moving average for the past 200 days.
Analysts’ Opinion of WINT
Many brokerage firms have already submitted their reports for WINT stocks, with Ladenburg Thalmann repeating the rating for WINT by listing it as a “Buy.” The predicted price for WINT in the upcoming period, according to Ladenburg Thalmann is $12.25 based on the research report published on June 26, 2020 of the previous year 2020.
WINT Trading at -35.02% from the 50-Day Moving Average
After a stumble in the market that brought WINT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.93% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at WINT starting from Fraser Craig, who purchase 5,431 shares at the price of $0.91 back on Oct 08 ’24. After this action, Fraser Craig now owns 8,638 shares of Windtree Therapeutics Inc, valued at $4,942 using the latest closing price.
Stock Fundamentals for WINT
Current profitability levels for the company are sitting at:
- -482.98 for the present operating margin
- 0.47 for the gross margin
The net margin for Windtree Therapeutics Inc stands at -461.09. The total capital return value is set at -1.07. Equity return is now at value -120.01, with -56.45 for asset returns.
Based on Windtree Therapeutics Inc (WINT), the company’s capital structure generated 0.58 points at debt to capital in total, while cash flow to debt ratio is standing at -10.53. The debt to equity ratio resting at 1.36. The interest coverage ratio of the stock is -107.59.
When we switch over and look at the enterprise to sales, we see a ratio of 47.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.25.
Conclusion
To wrap up, the performance of Windtree Therapeutics Inc (WINT) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
